43 research outputs found

    The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma

    No full text
    <div><p>Background</p><p>The impact of additional extra-hepatic primary cancer (EHPC) on the outcomes of patients with hepatocellular carcinoma (HCC) remains uncertain.</p><p>Methods</p><p>We retrospectively analyzed the cancer registration database from a tertiary hospital in Southern Taiwan. Patients who were diagnosed with HCC from 2008 to 2012 were enrolled. Overall survival (OS), HCC-specific survival and recurrence after curative therapy were analyzed and compared between the patients with and the patients without EHPC.</p><p>Results</p><p>EHPC was found in 121/1506 (8.0%) patients. HCC patients with EHPC were older, more likely to be classified as Child-Pugh A, less likely to have viral hepatitis B or C, more likely to be single, had early stage HCC and received curative therapy for HCC. The OS did not significantly differ between the patients with and without EHPC(p = 0.061). However, significantly higher HCC-specific survival was observed in patients with EHPC (p<0.001), and a higher rate of non-HCC mortality was demonstrated in patients with EHPC (54.4% vs 9.3%). The subgroup analysis revealed better OS in patients with EHPC who were older than 65, had viral hepatitis B or C, had non-stage 1 HCC, had non-early stage BCLC and received non-curative therapy. Conversely, patients with HCC stage 1 who received curative therapy exhibited worse OS if they also had EHPC. The analysis of recurrence after curative therapy showed no difference between the two groups.</p><p>Conclusions</p><p>Our results implied that EHPC did not affect OS, but HCC-related survival was better in patients with EHPC. Based on these findings, the management of additional primary cancer is warranted.</p></div

    Factors associated with HBeAg seroconversion plus HBV DNA <2000 IU/mL 12 months post-treatment in treatment experienced HBeAg-positive CHB patients.

    No full text
    <p>Continuous variables: median (25th, 75th percentiles); categorical variables: numbers(percentages)</p><p>IFN: interferon; ALT: alanine aminotransferase; ULN: upper limit of normal; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen</p><p>Factors associated with HBeAg seroconversion plus HBV DNA <2000 IU/mL 12 months post-treatment in treatment experienced HBeAg-positive CHB patients.</p

    Demographic data and baseline characteristics of all treatment-experienced CHB patients.

    No full text
    <p>Continuous variables: median (25th, 75th percentiles); categorical variables: numbers(percentages)</p><p>Missing data: genotype—2</p><p>IFN: interferon; NUC: nucleos(t)ide analogue; ALT: alanine aminotransferase; ULN: upper limit of normal; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen</p><p>Demographic data and baseline characteristics of all treatment-experienced CHB patients.</p
    corecore